Fury, M. G., Antonescu, C. R., Van Zee, K. J., Brennan, M. F., Maki, R. G. (May 2005) A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J, 11 (3). pp. 241-7. ISSN 1528-9117 (Print)1528-9117 (Linking)
Abstract
PURPOSE: Angiosarcoma is a rare vascular malignancy, and there are few published data to guide chemotherapy treatment decisions. We present a retrospective analysis of angiosarcoma encompassing all anatomic sites of disease presenting to a single institution over a 14-year period. Characteristics at presentation and prognostic factors are reviewed. For patients with unresectable disease, progression-free survival with various chemotherapy regimens is described. PATIENTS AND METHODS: Pathological confirmation of all cases was performed before they were included in this analysis. One hundred twenty-five patients with angiosarcoma were seen and treated between January 1, 1990 and December 31, 2003. RESULTS: Angiosarcoma showed marked variation by anatomic site regarding gender ratio, median age at diagnosis, overall survival, and response to chemotherapy. Overall 5-year survival was 31% for angiosarcoma. Superficial depth and negative microscopic surgical margins correlated with longer overall survival, but tumor size did not reach significance as a prognostic factor. For unresectable angiosarcoma, doxorubicin based regimens yielded progression-free survival of 3.7-5.4 months. Paclitaxel achieved a progression-free survival of 6.8 months for scalp angiosarcoma and 2.8 months for sites below the clavicle. DISCUSSION: Angiosarcoma is an aggressive malignancy characterized by biologic heterogeneity at different anatomic sites and relative sensitivity to paclitaxel and doxorubicin.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | Adult Age of Onset Aged Aged, 80 and over Antibiotics, Antineoplastic/*therapeutic use Antineoplastic Agents, Phytogenic/*therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Disease Progression Disease-Free Survival Doxorubicin/*therapeutic use Female *Hemangiosarcoma/drug therapy/pathology/surgery Humans Male Middle Aged *Neoplasm Staging Paclitaxel/*therapeutic use Prognosis Retrospective Studies Sex Factors |
| Subjects: | diseases & disorders > cancer > drugs and therapies > chemotherapy diseases & disorders > cancer > drugs and therapies diseases & disorders > cancer > prognosis diseases & disorders > cancer > cancer types > sarcoma |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matt Covey |
| Date: | May 2005 |
| Date Deposited: | 26 Oct 2016 20:23 |
| Last Modified: | 26 Oct 2016 20:23 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/33658 |
Actions (login required)
 |
Administrator's edit/view item |